Pharmaxis (ASX:PXS) and partner UK-based biotechnology company Synairgen have announced the leading compound of their LOXL2 inhibitor program will commence human clinical phase 1 studies later this year. …
Latest Video
New Stories
-
Entropy Neurodynamics clears safety hurdle for IV psilocin trial in binge eating disorder
June 15, 2026 - - Australian Biotech -
Paradigm reaches global milestone as Phase 3 osteoarthritis trial completes enrolment
June 15, 2026 - - Australian Biotech -
High Court to decide on patent‑term extensions for formulations as GBMA intervenes
June 15, 2026 - - Latest News -
Approach policy and pricing negotiations like planning for a product launch
June 15, 2026 - - Latest News -
The 'Dispatched' Week in Review'- 14 June
June 15, 2026 - - Podcast -
LifeSciences Australia honours outstanding professionals at MTP Sector Awards 2026
June 12, 2026 - - Latest News -
State and Territory ministers warn against centralising NDIS power
June 12, 2026 - - Latest News